FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, more specifically to genetically engineered compositions for therapeutic agent delivery into a patient's tumour, and may be used in medicine. The composition contains a therapeutically effective amount of a pharmaceutical composition of a functional Fc fragment of an antibody bound to one or more SPARC-binding polypeptides (SBP), and a pharmaceutically acceptable carrier. The composition is used in a method for delivery of a therapeutic agent containing the functional Fc fragment of the antibody.
EFFECT: invention provides the effective delivery of the therapeutic agent to the SPARC-expressing tumour in a mammal.
12 cl, 16 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| SINGLE-CHAIN TRAIL-RECEPTOR AGONIST PROTEINS | 2015 |
|
RU2699285C2 |
| ANTIBODIES TO FOLIC ACID RECEPTOR 1, THEIR IMMUNOCONJUGATES AND APPLICATION | 2011 |
|
RU2610663C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| RECOMBINANT IMMUNOTOXIN AIMED AT MESOTHELIN | 2012 |
|
RU2600067C2 |
| POLYPEPTIDES OF DIRECTED ACTION | 2006 |
|
RU2393874C2 |
| CD37 BINDING MOLECULES AND IMMUNOCONJUGATES | 2011 |
|
RU2610662C9 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| ANTI-MESOTHELIN IMMUNOCONJUGATES AND USE THEREOF | 2010 |
|
RU2575612C2 |
| SINGLE-STRANDED CD40 RECEPTOR AGONIST PROTEINS | 2016 |
|
RU2745801C2 |
| CONJUGATE OF ANGIOTENSIN PEPTIDE COMPONENT WITH CARRIER, VACCINE COMPOSITION, METHOD OF ANIMAL IMMUNISATION AND METHOD OF TREATMENT OR PREVENTION OF PHYSICAL DISORDER RELATED TO ANGIOTENSIN SYSTEM ACTIVATED BY RENIN | 2002 |
|
RU2350622C2 |
